Screener
Pulmonx Corporation LUNG Q3 2026 earnings
Reported October 27, 2026 · After market close
Revenue$22.8MBeat by $902.4K
EPS-$0.19Beat by $0.07
Revenue estimate$21.9M
EPS estimate-$0.26
“We are very pleased to have returned to year-over-year revenue growth in the third quarter. We continue to execute on our commercial strategy, advance our clinical initiatives, and deliver the operating leverage we expected. With a fully staffed U.S. sales leadership team, a more focused global commercial team, and a realigned cost structure, we are confident in our ability to build on this momentum and deliver growth while advancing our longer-term strategic priorities.”
Next report
Date not yet announcedValuation & ratios
Valuation
as of 10/27/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did Pulmonx Corporation report Q3 2026 earnings?
- Pulmonx Corporation (LUNG) reported Q3 2026 earnings on October 27, 2026 after market close.
- What were Pulmonx Corporation's Q3 2026 revenue and EPS?
- Pulmonx Corporation reported revenue of $22.8M and eps of $-0.19 for Q3 2026.
- Did Pulmonx Corporation beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $21.9M by $902.4K. EPS beat the consensus estimate of $-0.26 by $0.07.
- How did Pulmonx Corporation's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 6.2% from $21.5M a year earlier and eps grew 44.1% from $-0.34.
- Where can I find Pulmonx Corporation's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001127537-26-000042) directly on SEC EDGAR. The filing index links above go to sec.gov.
